Cytometric ploidy and proliferative activity in colorectal carcinoma. 1994

P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
Cattedra di Anatomia e Istologia Patologica, Università degli Studi di Brescia, Italy.

Thirty cases of colorectal carcinoma have been evaluated for proliferative activity with the monoclonal antibody Ki 67 and with flow cytometry for ploidy, DNA index and the S-phase fraction. In the series, 30% of tumours were strictly aneuploid, 23.8% tetraploid and 45% diploid: "non diploid" cases accounted for 53.8%. The mean comprehensive values of DNA index, percent S-phase and Ki 67 positive fraction were 1.4%, 11.5% and 50%, respectively. The parameters considered showed no statistically significant correlation with each other or with the common histo-pathologic parameters, such as grading and staging. The prevalent prognostic importance of ploidy compared to DNA index is emphasized, and particular attention is paid to diploid cases with a high growth fraction (S-phase fraction), which could make up an "at risk" category. Therefore, we attempted to identify subsets, within groups of the same histologic stage, with a different evolutive significance in relation to DNA content, percentage of positivity to Ki 67, S-phase fraction and ploidy. With such a multi-parametric approach, particular groups of patients at risk could be defined, which are perhaps more sensitive to specific support therapies.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D011003 Ploidies The degree of replication of the chromosome set in the karyotype. Ploidy
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell

Related Publications

P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
January 1998, Polish journal of pathology : official journal of the Polish Society of Pathologists,
P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
January 1995, Anticancer research,
P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
September 1995, Hepatology (Baltimore, Md.),
P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
January 1986, Basic and applied histochemistry,
P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
January 1982, Archives of dermatological research,
P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
March 1986, European journal of cancer & clinical oncology,
P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
January 1988, European urology,
P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
January 1998, Folia histochemica et cytobiologica,
P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
April 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
P Grigolato, and A Berenzi, and A Benetti, and E Chirico, and M Cadei, and C Casella, and B Salerni, and L Lojacono
January 1988, Cancer,
Copied contents to your clipboard!